Treos Bio Limited

Treos Bio Limited: A private, clinical stage company focused on peptide cancer immunotherapies computationally matched to patient genetics/immune response capability without need for tumor biopsy. Treos matches multiple tumor antigens and HLA genotypes achieving >10X increase in tumor target hit rate; platform broadly applicable to solid tumors. Pipeline includes personalized + off-the-shelf therapies for multiple solid cancers and an IND-ready 2nd generation COVID T-cell vaccine. Their lead programs include treatment for MSS colorectal cancer, with strong Ph1/2 results, and clinical collaborations with Roche and Mayo Clinic. Treos has $42M raised to date, with current investors including BXR Group, Conor Fund Seed Capital, Future Fund, Outsized Ventures (formerly Luminous Ventures), SPRIM Ventures, and The Hopkins Capital Group.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
COVID-19, Oncology
Industry
Biotechnology
Investment Participation
Series B
Listing
Private
Website:
Profiles:
Address:
The Harley Building
79 New Cavendish Street
London, W1W 6XB
United Kingdom

Company Participants at Solebury Trout Hamptons CEO Roundtable 2021

  • Christopher Gallen, CEO

Upcoming Company Event Participation